News & Media
SK life science
Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company
General business
Strategic alliance and partnership opportunities
Media inquiries and PR
Grant and investigator initiated proposals
Sponsorship requests
Medical information inquiries or report adverse events
Phone: 1-866-OKSKLSI (657-5574)
Email: medicalinfo@sklsi.com
SK life science at a glance
-
Headquarters location
PARAMUS, NJ
-
R&D Begins
1993
-
Parent Company
SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group
-
Number of employees
200+ EMPLOYEES
-
Disease Category Focus
CNS
-
Pipeline
8 compounds under clinical development
Newsroom
5/13/2019
SK life science Provides Update on Recent Company Milestones and Accomplishments
Full release5/03/2019
SK life science to Showcase Scientific Data at the 2019 American Academy of Neurology Annual Meeting
Full release2/15/2019
SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreement to Develop and Commercialize Cenobamate in Europe
Full release2/04/2019
SK life science announces FDA acceptance of NDA submission for cenobamate, an investigational antiepileptic drug
Full release12/03/2018
SK life science presents new data on its lead investigational compound, cenobamate, at the American Epilepsy Society 2018 Annual Meeting
Full release11/01/2018
SK life science honors Epilepsy Awareness Month with support for patients, advocates, caregivers, and healthcare providers
Full release5/15/2018
SK life science awards educational grant to J. Kiffin Penry Epilepsy Education Programs in support of neurology residents and epilepsy fellows
Full release4/23/2018
SK life science presents data on the investigational antiepileptic drug, cenobamate, at the American Academy of Neurology Annual Meeting 2018
Full release3/06/2018
SK life science to present data on cenobamate, an investigational antiepileptic compound, at ASCPT 2018 Annual Meeting
Full release11/29/2017
SK life science launches new corporate presence, expanded commercial operations in the United States.
Full release